MANE

Veradermics Inc

116.76

Oct 02 • 3:59 PM ET -0.46 (-0.39%)

116.76

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NYSE

Peers: ORKA KRYS RYTM BMRN VKTX ALNY INCY AXSM MDGL NBIX

| Held by: IWM VTI VXF JGRO SCHA IWO IHE VTWO XPH IWN

Index	RUT
Market Cap	4.88B
Enterprise Value	4.06B
Income	-
Sales	-
Book/sh	19.49
Cash/sh	19.62
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	21
IPO	Feb 04, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	5.99
P/C	5.95
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	70.53
Current Ratio	70.53
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-
EPS next Y	-2.63
EPS next Q	-0.61
EPS this Y	15.85%
EPS next Y	7.89%
EPS next 5Y	21.43%
EPS past 3/5Y	-117.94% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-44.05%
Sales Q/Q	-
Earnings	Aug 11 BMO
EPS/Sales Surpr.	11.40% -

Insider Own	27.61%
Insider Trans	-7.69%
Inst Own	69.93%
Inst Trans	22.94%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	6.65%
SMA50	8.72%
SMA200	29.93%
Trades

Shs Outstand	41.78M
Shs Float	30.25M
Short Float	13.58%
Short Ratio	5.70
Short Interest	4.11M
52W High	131.24 -11.03%
52W Low	32.00 264.88%
Volatility	5.49% 5.49%
ATR (14)	6.13
RSI (14)	59.18
Beta	-
Rel Volume	0.83
Avg Volume	719.99K
Volume	598,417

Perf Week	0.16%
Perf Month	18.59%
Perf Quarter	-4.35%
Perf Half Y	81.90%
Perf YTD	243.41%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	163.50
Prev Close	117.22
Price	116.76
Change %	-0.39%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-15-26	Initiated	B. Riley Securities	Buy	$170
Jun-02-26	Initiated	Needham	Buy	$136
Mar-02-26	Initiated	Leerink Partners	Outperform	$75
Mar-02-26	Initiated	Jefferies	Buy	$75
Mar-02-26	Initiated	Citigroup	Buy	$85
Mar-02-26	Initiated	Cantor Fitzgerald	Overweight

Sep-03-26 05:33PM	Veradermics to Present at Upcoming September Investor Conferences (Business Wire)
Aug-30-26 11:21PM	Hair Loss Biotechs Emerge As Wall Street's Newest Growth Trade (BeInCrypto)
Aug-11-26 06:11PM	Veradermics: Q2 Earnings Snapshot (Associated Press)
07:30AM	Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress (Business Wire)
Jul-17-26 07:30AM	Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study '302' in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy (Business Wire) +5.19%
09:35AM	Loading…
Jul-15-26 09:35AM	Veradermics shares climb 9% after encouraging female hair loss trial results (MANE) (InvestorsHub) +12.28%
07:00AM	Veradermics Oral VDPHL01 Delivers Positive Study 207 Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study 306 Readout (Business Wire)
Jul-14-26 06:54PM	Veradermics to Hold Conference Call to Discuss Study '207' Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss (Business Wire)
May-28-26 04:30PM	Veradermics to Present at Upcoming June Investor Conferences (Business Wire)
May-27-26 07:30AM	Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 302 Study of VDPHL01 at the 2026 World Congress for Hair Research (Business Wire)
May-15-26 04:52AM	The IPO Boom Isn't in Tech and AI-Yet (Barrons.com) -5.99%
May-14-26 01:09PM	Cerebras Swings IPO Focus to Tech and AI. But Healthcare and Industrials Still Lead. (Barrons.com)
07:30AM	Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium (Business Wire)
May-12-26 05:13PM	Veradermics: Q1 Earnings Snapshot (Associated Press)
07:30AM	Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress (Business Wire)
10:32PM	Loading…
Apr-29-26 10:32PM	Veradermics Announces Pricing of Upsized Public Offering and Private Placement (Business Wire) -7.09%
Apr-27-26 05:26PM	Veradermics Announces Launch of Public Offering (Business Wire) +47.55%
09:52AM	Veradermics Shares Jump 17% on Promising Hair Loss Trial Results (InvestorsHub)
09:31AM	How This Biotech, Up 25%, Is Taking A Page Out Of Rogaine's Playbook (Investor's Business Daily)
07:03AM	A new version of an old drug is helping men grow back some of their hair (MarketWatch)
07:00AM	Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 '302' Clinical Trial in Male Pattern Hair Loss (Business Wire)
Apr-26-26 04:00PM	Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 302 Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss (Business Wire)
Apr-01-26 01:13PM	Squawk Pod: OpenAI's eye-popping raise & hair today, hair forever - 04/01/26 Audio Only (CNBC TV) -6.92%
Mar-30-26 07:30AM	Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates (Business Wire) -7.14%
Mar-18-26 07:00AM	Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting (Business Wire)
Mar-03-26 07:00AM	Veradermics to Participate in Upcoming March Investor Conferences (Business Wire)
Feb-26-26 08:04PM	Flagship-Backed Generate Biomedicines Raises $400 Million in IPO (Bloomberg) +6.85%
07:39AM	For the first time in decades, new hair-loss treatments are in the works. Heres how theyre different. (MarketWatch)
Feb-25-26 03:36PM	For the first time in decades, new hair-loss treatments are in the works. Here's how they're different. (MarketWatch)
Feb-16-26 08:40AM	Reddit, KKR, and 2 Biotech IPOs Seeing the Love From Insiders (24/7 Wall St.)
08:55AM	Loading…
Feb-12-26 08:55AM	NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell (PR Newswire)
Feb-09-26 07:30AM	Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss (Business Wire)
Feb-06-26 04:18PM	Jennifer Garner's Once Upon a Farm Rises Nearly 20% To Wrap Up Busy Week for IPOs (Barrons.com)
Feb-05-26 04:05PM	Veradermics Announces Closing of Full Exercise of Underwriters Option to Purchase Additional Shares in Initial Public Offering (Business Wire)
Feb-04-26 04:12PM	No Revenue? No Problem. Biotech Targeting Hair Loss Doubles in Stock IPO. (Barrons.com)
01:07PM	This week's first IPO is set for a warm Wall Street welcome (MarketWatch)
08:55AM	NYSE Content Update: Disney Names New CEO After Ringing Bell on Main Street USA (PR Newswire)
Feb-03-26 09:57PM	Veradermics Announces Pricing of Upsized Initial Public Offering (Business Wire)

Veradermics, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company was founded in 2019 and is headquartered in New Haven, CT.

CEO & DirectorDr. Reid Waldman M.D.

CFO & TreasurerMr. Dominic Carrano CPA

Chief Technical OfficerDr. Timothy Durso M.D.

General Counsel & SecretaryMr. Michael V. Greco J.D.

Senior Director of Manufacturing Sciences & TechnologyMr. Karl Pruss

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MONTANOVA CAPITAL, LLC	Director	Aug 19 '26	Sale	107.25	750,000	80,437,500	461,033	Aug 21 06:11 PM
Averill Master Fund, Ltd.	Affiliate	Aug 19 '26	Proposed Sale	107.25	690,601	74,066,957		Aug 19 07:14 PM
Averill Madison Master Fund, L	Affiliate	Aug 19 '26	Proposed Sale	107.25	59,399	6,370,543		Aug 19 07:12 PM
Durso Timothy August	Chief Technical Officer	Aug 17 '26	Option Exercise	12.19	3,452	42,080	121,642	Aug 18 09:10 PM
Durso Timothy August	Chief Technical Officer	Aug 17 '26	Sale	107.82	43,500	4,690,005	78,142	Aug 18 09:10 PM
Waldman Reid Alexander	Chief Executive Officer	Aug 17 '26	Option Exercise	12.19	3,452	42,080	238,324	Aug 18 09:04 PM
Waldman Reid Alexander	Chief Executive Officer	Aug 17 '26	Sale	107.86	67,500	7,280,713	170,824	Aug 18 09:04 PM
Timothy Durso	Officer	Aug 17 '26	Proposed Sale	111.28	87,000	9,681,360		Aug 17 05:39 PM
Reid Alexander Waldman	CEO	Aug 17 '26	Proposed Sale	111.28	135,000	15,022,800		Aug 17 05:30 PM
CHILDS JOHN W	Director	Aug 12 '26	Sale	107.12	100,000	10,711,700	194,117	Aug 14 06:01 PM
AMZL, LP	Shareholder	Aug 12 '26	Proposed Sale	108.95	104,587	11,394,754		Aug 12 06:01 PM
SR One Capital Fund II Aggrega	Shareholder	Aug 12 '26	Proposed Sale	108.95	217,162	23,659,800		Aug 12 06:00 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Feb 04 '26	Buy	37.05	155,953	5,778,342	3,648,538	Feb 09 06:28 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Feb 05 '26	Buy	37.99	96,200	3,655,079	489,932	Feb 09 06:28 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Feb 06 '26	Buy	36.34	30,521	1,109,056	520,453	Feb 09 06:28 PM
Coric Vlad	Director	Feb 05 '26	Buy	17.00	117,646	1,999,982	319,398	Feb 05 07:04 PM
CHILDS JOHN W	Director	Feb 05 '26	Buy	17.00	294,117	4,999,989	2,202,006	Feb 05 07:04 PM
Longitude Capital Partners V,	10% Owner	Feb 05 '26	Buy	17.00	1,075,000	18,275,000	2,600,399	Feb 05 07:03 PM
ENRIGHT PATRICK G	Director	Feb 05 '26	Buy	17.00	1,075,000	18,275,000	2,600,399	Feb 05 07:03 PM

Open in Screener

VERA

Vera Therapeutics Inc

30.42

Oct 02 • 3:59 PM ET -0.57 (-1.84%)

30.42

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

VERA Vera Therapeutics Inc daily Stock Chart

Peers: CGON KYMR RYTM AXSM BMRN CRNX APGE INCY KRYS NBIX

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA FESM DFMC

Index	RUT
Market Cap	2.19B
Enterprise Value	1.77B
Income	-401.89M
Sales	0.00M
Book/sh	5.67
Cash/sh	6.93
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	249
IPO	May 14, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	5.37
P/C	4.39
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	10.65
Current Ratio	10.65
Debt/Eq	0.18
LT Debt/Eq	0.18
Option/Short	Yes / Yes

EPS (ttm)	-5.87
EPS next Y	-4.35
EPS next Q	-1.61
EPS this Y	-33.80%
EPS next Y	30.29%
EPS next 5Y	53.56%
EPS past 3/5Y	-11.65% -13.19%
Sales past 3/5Y	- -
EPS Y/Y TTM	-63.94%
Sales Y/Y TTM	-
EPS Q/Q	-27.01%
Sales Q/Q	-
Earnings	Aug 10 AMC
EPS/Sales Surpr.	3.54% -

Insider Own	18.81%
Insider Trans	-1.05%
Inst Own	98.38%
Inst Trans	8.15%
ROA	-72.32%
ROE	-91.75%
ROIC	-83.21%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-9.11%
SMA50	-8.05%
SMA200	-22.04%
Trades

Shs Outstand	71.96M
Shs Float	58.51M
Short Float	29.11%
Short Ratio	7.29
Short Interest	17.04M
52W High	56.05 -45.73%
52W Low	23.05 31.97%
Volatility	4.49% 5.87%
ATR (14)	1.87
RSI (14)	38.20
Beta	1.05
Rel Volume	0.69
Avg Volume	2.34M
Volume	1,614,860

Perf Week	-6.52%
Perf Month	-14.69%
Perf Quarter	-24.20%
Perf Half Y	-25.55%
Perf YTD	-39.93%
Perf Year	4.21%
Perf 3Y	134.90%
Perf 5Y	67.33%
Perf 10Y	-
Recom	1.14
Target Price	77.50
Prev Close	30.99
Price	30.42
Change %	-1.84%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-26	Upgrade	Wolfe Research	Peer Perform → Outperform	$88
Oct-16-25	Initiated	BofA Securities	Buy	$48
Aug-04-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-05-25	Resumed	H.C. Wainwright	Buy	$75
Feb-04-25	Initiated	Wolfe Research	Outperform	$49
Jan-28-25	Initiated	Goldman	Buy	$58
Nov-21-24	Initiated	Wells Fargo	Overweight	$70
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jan-25-24	Initiated	Oppenheimer	Outperform	$26
Jan-08-24	Initiated	Cantor Fitzgerald	Overweight
Dec-18-23	Initiated	Raymond James	Outperform	$29
Nov-10-23	Upgrade	Jefferies	Hold → Buy	$18 → $26
Aug-16-23	Initiated	Guggenheim	Buy	$27
Jan-04-23	Downgrade	Wedbush	Outperform → Neutral	$33 → $8
Jan-04-23	Downgrade	Jefferies	Buy → Hold	$32 → $6
Jul-12-22	Initiated	JP Morgan	Overweight	$35
May-02-22	Initiated	H.C. Wainwright	Buy	$35
Apr-19-22	Initiated	Wedbush	Outperform	$32

Show Previous Ratings

Oct-02-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:24AM	Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 (GlobeNewswire)
Sep-15-26 09:51PM	Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run Here Are The Stocks And Catalysts To Watch Next (Stocktwits) -5.64%
12:39PM	Vera set up for full approval for Trutakna in IgAN with Phase III win (Clinical Trials Arena)
12:03PM	Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results (Barrons.com)
10:33AM	Loading…
10:33AM	Vera Stock Slides Despite Positive Phase 3 Results (Schaeffer's Research)
09:37AM	Vera Therapeutics Shares Rise 13% After TRUTAKNA Meets ORIGIN 3 Trial Endpoints (InvestorsHub)
09:08AM	VERA Stock Jumps 16% Premarket Trutakna Cuts Kidney Disease Progression Risk By 76%, Full FDA Filing Planned In Q4 (Stocktwits)
06:30AM	Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy (GlobeNewswire)
Sep-04-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-01-26 07:30AM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-10-26 04:05PM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Aug-07-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-10-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-09-26 08:00AM	Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner (GlobeNewswire)
02:43PM	Loading…
Jul-07-26 02:43PM	?? Under the Radar: Vera Stock Jumps as Kidney-Disease Drug Approved by FDA (The Wall Street Journal) +7.05%
02:33PM	VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval Retail Sees The Move As Catalyst For Vera Therapeutics (Stocktwits)
12:37PM	Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA for Adult Patients with Primary IgA Nephropathy (GlobeNewswire)
03:47AM	Vera Therapeutics wins FDA nod for closely watched kidney disease drug (BioPharma Dive)
Jul-06-26 09:10AM	Vera Therapeutics Shares Climb Ahead of FDA Decision on Atacicept (VERA) (InvestorsHub)
08:19AM	Scilex, Vera Therapeutics rise premarket; Strategy gains (Investing.com)
06:53AM	VERA Stock Rallies Ahead Of High-Stakes FDA Decision On Lead Kidney Disease Drug Retail Sees 35% Potential Upside (Stocktwits)
Jun-05-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-26 12:51PM	Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment (Stocktwits) -7.90%
07:00AM	Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy (GlobeNewswire)
May-08-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-07-26 07:30AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-04-26 07:30AM	Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference (GlobeNewswire)
Apr-10-26 04:30PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.04%
Mar-27-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:30AM	Loading…
Mar-25-26 07:30AM	Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer (GlobeNewswire)
Mar-06-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-26 09:00AM	Vera Therapeutics Appoints Christopher Hite to Board of Directors (GlobeNewswire)
Feb-26-26 07:30AM	Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results (GlobeNewswire)
Feb-24-26 08:00AM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Feb-18-26 07:39PM	Analysts Bullish on Vera Therapeutics (VERA) Amid New Commercial Chief Appointment (Insider Monkey)
Feb-16-26 12:23PM	Atacicept's Potential Approval Drives Favorable Views on Vera Therapeutics (VERA) (Insider Monkey)
Feb-07-26 11:35AM	Vera Therapeutics, Inc. (VERA): A Bull Case Theory (Insider Monkey)
Feb-06-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.23%
Jan-30-26 12:24AM	Is Vera Therapeutics (VERA) One of the Best High Short Interest Stocks with Biggest Upside Potential? (Insider Monkey)
Jan-28-26 07:30AM	Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer (GlobeNewswire)
Jan-23-26 11:09AM	Clinical Success Lifts Vera (VERA) Shares, Boosting Fund Returns (Insider Monkey)
Jan-15-26 11:35AM	Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept (Insider Monkey)
Jan-14-26 09:55AM	Wall Street Analysts See a 53.05% Upside in Vera Therapeutics (VERA): Can the Stock Really Move This High? (Zacks)
Jan-09-26 01:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-26 07:30AM	Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-26 07:41PM	Why Vera Therapeutics Stock Zoomed Higher Today (Motley Fool)
07:30AM	Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy (GlobeNewswire)
Dec-09-25 08:57PM	Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock (GlobeNewswire)
Dec-08-25 04:01PM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
Dec-05-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.37%
Dec-02-25 07:42PM	Why Vera Therapeutics Stock Rocked the Market on Tuesday (Motley Fool) +12.88% +10.77%
01:09PM	Stock Market Today: MongoDB, Boeing, and Intel Define Tuesday Trade As Market Bounces Back From Post-Thanksgiving Blues (TheStreet)
Nov-26-25 07:45PM	Why Vera Therapeutics Stock Crushed it Today (Motley Fool) +13.25%
04:05PM	Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors (GlobeNewswire)
Nov-24-25 07:25AM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-18-25 02:20PM	Vera Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-16-25 10:14PM	H.C. Wainwright Maintains Its Bullish Stance on Vera Therapeutics (VERA), Sees Strong Future Revenue Growth (Insider Monkey)
Nov-14-25 09:01AM	Yale University's Strategic Investment in Vera Therapeutics Inc: A 32.26% Portfolio Stake (GuruFocus.com)
Nov-10-25 07:29AM	Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit (GlobeNewswire) +14.72%
Nov-07-25 06:27PM	Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy (GlobeNewswire)
04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 09:51AM	Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine (GlobeNewswire)
Nov-05-25 07:29AM	Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-22-25 08:00AM	Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET (GlobeNewswire)
Oct-20-25 11:08PM	BofA Initiates Coverage of Vera Therapeutics (VERA) With a Buy Rating (Insider Monkey)
Oct-17-25 09:12AM	Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025 (GlobeNewswire)
Oct-10-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.46%
Aug-26-25 04:05PM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire) +5.62%
Aug-08-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-25 07:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 09:35AM	Coinbase downgraded, Spotify upgraded: Wall Street's top analyst calls (The Fly)
Jul-10-25 07:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-02-25 08:07AM	Millions in Insider Buying Point to These 2 Stocks Heres What It Could Signal (TipRanks)
Jun-12-25 01:57PM	Analysts Can't Get Enough of These Little-Known Biopharma Stocks (MarketBeat)
Jun-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 11:02AM	Biotech Stock Vera Is Slumping After Monster Gain (Barrons.com) -25.89%
07:49AM	Vera Therapeutics stock sinks following competitors successful trial (Investing.com)
Jun-04-25 04:05PM	Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-25 06:30AM	Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans (GlobeNewswire)
02:22AM	Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday (Insider Monkey)
Jun-02-25 06:30AM	Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy (GlobeNewswire) +67.49%
04:51AM	Vera drug scores in closely watched study in rare kidney disease (BioPharma Dive)
May-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-06-25 08:00AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results (GlobeNewswire) -13.79%
Apr-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +16.76%
02:51PM	Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch (Benzinga)
Apr-03-25 08:00AM	Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN (GlobeNewswire)
Mar-11-25 04:28PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 08:00AM	Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) +5.91%
Feb-26-25 08:25AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-13-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -19.66%
Jan-14-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-13-25 07:00AM	Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor (GlobeNewswire) -6.08%
Jan-07-25 04:05PM	Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 06:29PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-22-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-18-24 08:00AM	Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer (GlobeNewswire)
Nov-11-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Vera Therapeutics, Inc. is a clinical stage biotechnical company, which engages in the development and commercialization of transformative treatments for immunological diseases. Its product includes the TRUTAKNA injection. The company was founded by Marshall W. Fordyce in May 2016 and is headquartered in Brisbane, CA.

FounderDr. Marshall W. Fordyce M.D.

Chief Financial OfficerMr. Sean P. Grant M.B.A.

Chief Opearating OfficerMr. David L. Johnson M.B.A.

Chief Medical OfficerDr. Robert M. Brenner M.D.

Senior VP of Finance & Chief Accounting OfficerMr. Joseph R. Young M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fordyce Marshall	PRESIDENT AND CEO	Sep 15 '26	Option Exercise	2.90	18,500	53,591	253,744	Sep 17 04:28 PM
Fordyce Marshall	PRESIDENT AND CEO	Sep 15 '26	Sale	37.00	18,500	684,500	235,244	Sep 17 04:28 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Sep 11 '26	Option Exercise	3.94	5,000	19,698	80,754	Sep 14 04:28 PM
Fordyce Marshall	PRESIDENT AND CEO	Sep 02 '26	Option Exercise	2.90	18,500	53,591	253,744	Sep 04 04:15 PM
Fordyce Marshall	PRESIDENT AND CEO	Sep 02 '26	Sale	35.12	18,500	649,642	235,244	Sep 04 04:15 PM
MARSHALL FORDYCE	Director	Sep 02 '26	Proposed Sale	34.23	64,750	2,216,392		Sep 02 04:32 PM
Fordyce Marshall	PRESIDENT AND CEO	Jul 07 '26	Sale	42.30	46,250	1,956,187	151,994	Jul 09 04:45 PM
Fordyce Marshall	PRESIDENT AND CEO	Jun 23 '26	Sale	37.93	18,500	701,769	198,244	Jun 24 04:55 PM
MARSHALL FORDYCE	Director	Jun 23 '26	Proposed Sale	38.43	74,000	2,843,820		Jun 23 04:29 PM
Fordyce Marshall	PRESIDENT AND CEO	May 12 '26	Sale	36.74	18,500	679,747	216,744	May 13 04:26 PM
MARSHALL FORDYCE	Director	May 12 '26	Proposed Sale	36.61	18,500	677,285		May 12 04:33 PM
Fordyce Marshall	PRESIDENT AND CEO	Apr 14 '26	Sale	44.05	22,951	1,011,051	235,244	Apr 15 04:57 PM
MARSHALL FORDYCE	Director	Apr 14 '26	Proposed Sale	43.71	22,951	1,003,188		Apr 14 04:33 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Mar 13 '26	Option Exercise	3.94	10,000	39,396	75,754	Mar 16 06:52 PM
Brenner Robert	Chief Medical Officer	Feb 23 '26	Sale	41.98	2,151	90,307	50,947	Feb 25 08:01 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Feb 23 '26	Sale	41.98	3,117	130,864	64,722	Feb 25 08:00 PM
Grant Sean	CHIEF FINANCIAL OFFICER	Feb 23 '26	Sale	41.98	4,949	207,778	114,181	Feb 25 07:59 PM
Fordyce Marshall	PRESIDENT AND CEO	Feb 23 '26	Sale	41.98	16,925	710,578	257,163	Feb 25 07:58 PM
JOHNSON DAVID LEE	Chief Operating Officer	Feb 23 '26	Sale	41.98	2,579	108,276	45,727	Feb 25 07:57 PM
Turner William D.	Chief Regulatory Officer	Feb 23 '26	Sale	41.98	2,187	91,819	45,313	Feb 25 07:56 PM
Skelton Laurence Matthew	Chief Commercial Officer	Feb 23 '26	Sale	41.98	1,582	66,419	64,218	Feb 25 07:53 PM
LAURENCE SKELTON	Officer	Feb 23 '26	Proposed Sale	42.03	1,800	75,663		Feb 23 04:44 PM
WILLIAM DONALD TURNER	Officer	Feb 23 '26	Proposed Sale	42.03	2,600	109,291		Feb 23 04:42 PM
SEAN GRANT	Officer	Feb 23 '26	Proposed Sale	42.03	5,700	239,600		Feb 23 04:41 PM
ROBERT BRENNER	Officer	Feb 23 '26	Proposed Sale	42.03	2,500	105,088		Feb 23 04:39 PM
DAVID L JOHNSON	Officer	Feb 23 '26	Proposed Sale	42.03	2,900	121,902		Feb 23 04:31 PM
MARSHALL FORDYCE	Officer	Feb 23 '26	Proposed Sale	42.03	16,600	697,781		Feb 23 04:29 PM
Turner William D.	Chief Regulatory Officer	Dec 15 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 17 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 15 '25	Sale	50.08	10,000	500,767	22,500	Dec 17 04:05 PM
ENRIGHT PATRICK G	Director	Dec 11 '25	Buy	42.50	5,882	249,985	5,882	Dec 15 08:07 PM
WILLIAM TURNER	Officer	Dec 15 '25	Proposed Sale	49.80	10,000	498,000		Dec 15 04:17 PM
Turner William D.	Chief Regulatory Officer	Dec 08 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 10 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 08 '25	Sale	45.31	10,000	453,053	22,500	Dec 10 04:05 PM
WILLIAM TURNER	Officer	Dec 08 '25	Proposed Sale	44.90	10,000	449,000		Dec 08 04:41 PM
Turner William D.	Chief Regulatory Officer	Dec 03 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 04 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 03 '25	Sale	40.00	10,000	400,000	22,500	Dec 04 04:05 PM
WILLIAM TURNER	Officer	Dec 03 '25	Proposed Sale	37.25	10,000	372,500		Dec 03 04:31 PM
Carter Jason S	Chief Legal Officer	Nov 21 '25	Sale	27.82	3,864	107,498	49,136	Nov 25 04:05 PM
Carter Jason S	Officer	Nov 21 '25	Proposed Sale	27.87	3,864	107,690		Nov 24 09:22 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Nov 13 '25	Option Exercise	3.94	10,000	39,396	57,839	Nov 13 08:57 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Nov 11 '25	Sale	29.06	15,000	435,874	47,839	Nov 13 08:57 PM

Open in Screener

ZBIO

Zenas Biopharma Inc

28.30

Oct 02 • 3:59 PM ET +0.35 (1.27%)

28.55

Aftermarket • 4:15 PM ET +0.25 (0.90%)

Healthcare Biotechnology USA Small NASD

ZBIO Zenas Biopharma Inc daily Stock Chart

Peers: RYTM KYMR VKTX BMRN CRNX INCY KRYS AXSM MDGL NBIX

| Held by: XBI VTI IWM VXF IWO IBB SCHA VTWO IWC VHT

Index	RUT
Market Cap	1.84B
Enterprise Value	1.59B
Income	-484.38M
Sales	1.00M
Book/sh	3.90
Cash/sh	9.87
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	167
IPO	Sep 13, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	1844.18
P/B	7.25
P/C	2.87
P/FCF	-
EV/EBITDA	-
EV/Sales	1590.65
Quick Ratio	9.93
Current Ratio	9.93
Debt/Eq	1.58
LT Debt/Eq	1.57
Option/Short	Yes / Yes

EPS (ttm)	-9.61
EPS next Y	-5.06
EPS next Q	-1.24
EPS this Y	33.25%
EPS next Y	10.20%
EPS next 5Y	23.61%
EPS past 3/5Y	-39.47% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-127.13%
Sales Y/Y TTM	-93.33%
EPS Q/Q	-41.57%
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	-57.71% -93.33%

Insider Own	49.20%
Insider Trans	0.38%
Inst Own	74.92%
Inst Trans	22.69%
ROA	-97.39%
ROE	-199.04%
ROIC	-76.18%
Gross Margin	96.90%
Oper. Margin	-27390.10%
Profit Margin	-48438.40%
SMA20	-6.81%
SMA50	-9.38%
SMA200	11.94%
Trades

Shs Outstand	63.33M
Shs Float	33.11M
Short Float	35.85%
Short Ratio	16.09
Short Interest	11.87M
52W High	44.60 -36.56%
52W Low	13.50 109.59%
Volatility	6.82% 6.36%
ATR (14)	1.96
RSI (14)	41.86
Beta	-0.87
Rel Volume	2.05
Avg Volume	737.66K
Volume	1,513,616

Perf Week	4.99%
Perf Month	-14.59%
Perf Quarter	6.98%
Perf Half Y	31.85%
Perf YTD	-22.07%
Perf Year	35.06%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.25
Target Price	47.88
Prev Close	27.94
Price	28.30
Change %	1.27%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19
Mar-20-25	Initiated	Wedbush	Outperform	$35
Feb-04-25	Initiated	Wolfe Research	Outperform	$19
Dec-16-24	Initiated	H.C. Wainwright	Buy	$30
Nov-05-24	Initiated	Rodman & Renshaw	Buy	$34
Oct-08-24	Initiated	Morgan Stanley	Overweight	$40
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$45
Oct-08-24	Initiated	Citigroup	Buy	$27

Sep-22-26 07:05AM	Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026 (GlobeNewswire)
Sep-18-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-08-26 07:05AM	Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event (GlobeNewswire)
Sep-04-26 07:05AM	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire)
Aug-28-26 07:46PM	Fortune Brands and 4 More Stocks See Action From Activist Investors (Barrons.com)
04:15PM	Loading…
Aug-18-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-13-26 07:00AM	Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -6.68%
Jul-17-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-17-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.46%
Jun-11-26 04:15PM	Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit (GlobeNewswire) +11.49%
Jun-02-26 07:05PM	Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine (GlobeNewswire) -5.72%
May-28-26 07:05AM	Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD (GlobeNewswire)
May-19-26 07:05AM	Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress (GlobeNewswire) +5.50%
May-18-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.80%
May-13-26 06:50AM	Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor (GlobeNewswire)
06:00AM	Loading…
06:00AM	Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-17-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-26 12:12AM	Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million (GlobeNewswire) -17.82%
Mar-26-26 04:01PM	Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock (GlobeNewswire)
Mar-16-26 06:01PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-28-26 10:56AM	Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory (Insider Monkey)
Feb-20-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-26 07:09AM	Encouraging Phase II Trial Data Supported Zenas BioPharma, Inc. (ZBIO) in Q4 (Insider Monkey)
Feb-16-26 04:07AM	Zenas BioPharma Highlights Obexelimab Phase 3 Win, Targets Q2 BLA Filing at Guggenheim Summit (MarketBeat)
Feb-09-26 07:05AM	Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 (GlobeNewswire)
Feb-04-26 07:05AM	Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-16-26 04:15PM	Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-10-26 09:01AM	Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Benzinga)
Jan-07-26 06:46AM	Zenas BioPharma Touts Phase 3 Win, But Stock Crashes (Benzinga) +8.62%
11:18AM	Loading…
Jan-06-26 11:18AM	ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study (Zacks) -8.49%
06:25AM	Zenas stock drops 51% despite lead assets Phase III rare disease win (Clinical Trials Arena)
Jan-05-26 04:23PM	Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed. (Investor's Business Daily) -51.86%
07:05AM	Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) (GlobeNewswire)
06:26AM	Zenas shares crash after top drug misses expectations in immune disease study (BioPharma Dive)
Dec-19-25 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +17.10%
Dec-15-25 07:05AM	Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus (GlobeNewswire) -19.71%
Dec-12-25 09:45AM	Huge Insider Buying in MGM and Salesforce (24/7 Wall St.)
Dec-03-25 07:25AM	Meridian Small Cap Growth Fund Trimmed Zenas BioPharma (ZBIO) Following Share Price Appreciation (Insider Monkey) +6.29%
Nov-12-25 07:05AM	Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-11-25 07:05AM	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire) +8.41%
Oct-31-25 12:41PM	How Royalty Pharma Prints Cash Without Biotech's Biggest Risks (MarketBeat)
Oct-28-25 01:34PM	1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data (MarketBeat) -5.06%
08:35AM	Zenas bifunctional mAb scores at Phase II in relapsing MS (Clinical Trials Arena)
06:00AM	Incyte trims pipeline; Zenas surges on MS drug results (BioPharma Dive)
Oct-27-25 07:05AM	Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis (GlobeNewswire) +33.08%
Oct-08-25 05:00AM	Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis (GlobeNewswire) +24.22%
Sep-02-25 07:05AM	Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million (GlobeNewswire) +9.50%
Aug-26-25 07:05AM	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire)
Aug-12-25 07:05AM	Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +6.68%
Jun-20-25 04:15PM	Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-13-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -8.75%
Jun-02-25 04:00AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) +5.67%
May-29-25 07:05AM	Zenas BioPharma to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +8.34%
May-28-25 09:31AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) -12.59%
May-16-25 05:45AM	Investors in Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +7.49%
May-15-25 07:05AM	Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +12.21%
May-06-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -19.71%
May-02-25 05:45AM	Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire)
Apr-29-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +12.56%
Apr-22-25 10:37AM	Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses (GlobeNewswire)
Apr-21-25 12:33PM	Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses (GlobeNewswire) +9.30%
Apr-17-25 04:20PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.08%
Apr-07-25 03:08PM	Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst (Seeking Alpha)
07:05AM	Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Mar-20-25 02:54PM	Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress (Benzinga)
11:41AM	Zenas Bio rises as Wedbush launches with Outperform on lead asset (SeekingAlpha)
Mar-17-25 07:05AM	Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer (GlobeNewswire)
Feb-05-25 07:05AM	Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases (GlobeNewswire)
Jan-28-25 08:00AM	Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-17-24 06:25AM	Zenas BioPharma initiated with a Buy at H.C. Wainwright (TipRanks) +8.10%
Dec-12-24 07:35AM	Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley (TipRanks)
Nov-12-24 07:10AM	Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
07:05AM	Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) (GlobeNewswire)
Nov-07-24 07:05AM	Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks) +7.63%
Sep-19-24 04:15PM	Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering (GlobeNewswire) +8.45%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 10:37PM	Zenas BioPharma Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

M.B.A.Mr. Leon Oliver Moulder Jr.

COO & PresidentMr. Joseph L. Farmer

Head of Research & Development and Chief Medical OfficerDr. Lisa von Moltke M.D.

Chief Business Officer & CFOMs. Jennifer A. Fox

Chief Technical OfficerDr. Heinrich Schlieker Ph.D.